Efficacy of oncolytic reovirus against human gastric cancer with peritoneal metastasis in experimental animal model

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1433-1438

  Kawaguchi, Koji ^a   Etoh, Tsuyoshi ^a   Suzuki, Kosuke ^a   Mitui, Marcelo Takahiro ^a   Nishizono, Akira ^a   Shiraishi, Norio ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Gastric cancer; Peritoneal metastasis; Reovirus

Indexed keywords

ONCOLYTIC REOVIRUS; ONCOLYTIC VIRUS; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PERITONEUM METASTASIS; PRIORITY JOURNAL; STOMACH CANCER;

EID: 78649958684     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000795     Document Type: Article

References (38)

1. Murray CJ and Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 349: 1498-1504, 1997.
2. Japanese Gastric Cancer Association: Gastric cancer treatment guidelines for doctors' reference (in Japanese). Kanehara, Tokyo, 2004.
3. Kitayama J, Ishigami H, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H and Nagawa H: Weekly intravenous and intraperitoneal paclitaxel combined with S-1 for malignant ascites due to advanced gastric cancer. Oncology 78: 40-46, 2010.
4. Imazawa M, Kojima T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yasui H, Yamazaki K and Taku K: Efficacy of sequential methotrexate and 5-fluorouracil (MTX/5FU) in improving oral intake in patients with advanced gastric cancer with severe peritoneal dissemination. Gastric Cancer 12: 153-157, 2009.
5. Okabe H, Ueda S, Obama K, Hosogi H and Sakai Y: Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 16: 3227-3236, 2009.
6. Mochiki E, Shioya M, Sakurai H, Andoh H, Ohno T, Aihara R, Asao T and Kuwano H: Feasibility study of postoperative intraperitoneal hyperthermochemotherapy by radiofrequency capacitive heating system for advanced gastric cancer with peritoneal seeding. Int J Hyperthermia 23: 493-500, 2007. (Pubitemid 350011519)
7. Yonemura Y, Kawamura T, Bandou E, Takahashi S, Sawa T and Matsuki N: Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion. Br J Surg 92: 370-375, 2005. (Pubitemid 40445602)
8. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998. (Pubitemid 28279509)
9. Etoh T, Himeno Y, Matsumoto T, Aramaki M, Kawano K, Nishizono A and Kitano S: Oncolytic viral therapy for human pancreatic cancer cells by reovirus. Clin Cancer Res 9: 1218-1223, 2003. (Pubitemid 36323732)
10. Himeno Y, Etoh T, Matsumoto T, Ohta M, Nishizono A and Kitano S: Efficacy of oncolytic reovirus against liver metastasis from pancreatic cancer in immunocompetent models. Int J Oncol 27: 901-906, 2005.
11. Hirano S, Etoh T, Okunaga R, Shibata K, Ohta M, Nishizono A and Kitano S: Reovirus inhibits the peritoneal dissemination of pancreatic cancer cells in an immunocompetent animal model. Oncol Rep 21: 1381-1384, 2009.
12. Forsyth P, Roldán G, George D, Wallace C, Palmer CA, Morris D, Cairncross G, Matthews MV, Markert J, Gillespie Y, Coffey M, Thompson B and Hamilton M: A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther 16: 627-632, 2008.
13. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A and Lee PW: Oncolytic reovirus against ovarian and colon cancer. Cancer Res 62: 1696-1701, 2002.
14. Hata Y, Etoh T, Inomata M, Shiraishi N, Nishizono A and Kitano S: Efficacy of oncolytic reovirus against human breast cancer cells. Oncol Rep 19: 1395-1398, 2008.
15. Smith RE, Zweerink HJ and Joklik WK: Polypeptide components of virions, top component and cores of reovirus type 3. Virology 39: 791-810, 1969.
16. Lee PW, Hayes EC and Joflik WK: Protein sigma 1 is the reovirus cell attachment protein. Virology 108: 156-163, 1981.
17. Wilcox ME, Yang W, Senger D, Rewcastle NB, Morris DG, Brasher PM, Shi ZQ, Johnston RN, Nishikawa S, Lee PW and Forsyth PA: Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 93: 903-912, 2001.
18. Alain T, Hirasawa K, Pon KJ, et al: Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153, 2002.
19. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK and Kim WH: EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology 52: 738-746, 2008.
20. Sei S, Mussio JK, Yang QE, Nagashima K, Parchment RE, Coffey MC, Shoemaker RH and Tomaszewski JE: Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 14: 47, 2009.
21. van Houdt WJ, Smakman N, van den Wollenberg DJ, Emmink BL, Veenendaal LM, van Diest PJ, Hoeben RC, Borel Rinkes IH and Kranenburg O: Transient infection of freshly isolated human colorectal tumor cells by reovirus T3D intermediate subviral particles. Cancer Gene Ther 15: 284-292, 2008. (Pubitemid 351508137)
22. Norman KL, Hirasawa K, Yang AD, Shields MA and Lee PW: Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 101: 11099-11104, 2004. (Pubitemid 38989590)
23. Barton ES, Forrest JC, Connolly JL, Chappell JD, Liu Y, Schnell FJ, Nusrat A, Parkos CA and Dermody TS: Junction adhesion molecule is a receptor for reovirus. Cell 104: 441-451, 2001. (Pubitemid 32206464)
24. Strong JE and Lee PW: The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 70: 612-616, 1996.
25. Chappell JD, Gunn VL, Wetzel JD, Baer GS and Dermody TS: Mutations in type 3 reovirus that determine binding to sialic acid are contained in the fibrous tail domain of viral attachment protein sigma1. J Virol 71: 1834-1841, 1997.
26. Golden JW, Linke J, Schmechel S, Thoemke K and Schiff LA: Addition of exogenous protease facilitates reovirus infection in many restrictive cells. J Virol 76: 7430-7443, 2002.
27. Alain T, Kim TS, Lun X, Liacini A, Schiff LA, Senger DL and Forsyth PA: Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther 15: 1512-1521, 2007
28. Cho IR, Koh SS, Min HJ, Park EH, Srisuttee R, Jhun BH, Kang CD, Kim M, Johnston RN and Chung YH: Reovirus infection induces apoptosis of TRAIL-resistant gastric cancer cells by down-regulation of Akt activation. Int J Oncol 36: 1023-1030, 2010.
29. Link CJ, Moorman DW, Ackerman M, Levy JP and Seregina T: Murine retroviral vector producer cells survival and toxicity in the peritoneal cavity of dogs. In Vivo 14: 635-641, 2000.
30. Gordon EM, Chen ZH, Liu L, Whitley M, Wei D, Groshen S, Hinton DR, Anderson WF, Beart RW Jr and Hall FL: Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum Gene Ther 12: 193-204, 2001. (Pubitemid 32095457)
31. Tam P, Monck M, Lee D, Ludkovski O, Leng EC, Clow K, Stark H, Scherrer P, Graham RW and Cullis PR: Stabilized plasmid-lipid particles for systemic gene therapy. Gene Ther 7: 1867-1874, 2000.
32. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG and Löwenstein PR: Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 5: 1256-1263, 1999. (Pubitemid 29535602)
33. Mastrangelo MJ, Maguire HC Jr, Eisenlohr LC, Laughlin CE, Monken CE, McCue PA, Kovatich AJ and Lattime EC: Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther 6: 409-422, 1999.
34. Pecora AL, Rizvi N, Cohen GI, Meropol NJ, Sterman D, Marshall JL, Goldberg S, Gross P, O'Neil JD, Groene WS, Roberts MS, Rabin H, Bamat MK and Lorence RM: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20: 2251-2266, 2002.
35. Nemunaitis J, Cunningham C, Buchanan A, Blackburn A, Edelman G, Maples P, Netto G, Tong A, Randlev B, Olson S and Kirn D: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8: 746-759, 2001.
36. Morris D, Forsyth PA, Patherson AH, et al: A phase I clinical trial evaluating intralesional Reolysin (reovirus) in histologically confirmed malignancies. Proc Am Soc Clin Oncol Annu Meet 21: 92:24, 2002.
37. Comins C, Spicer J, Protheroe A, Mukherji D, Coffey M, Thompson B, Harrington K and Pandha H: A phase I study to evaluate systemic wild-type reovirus (Reolysin) in combination with docetaxel in patients with advanced malignancies. In: International Society for Biological Therapy of Cancer 23rd Annual Meeting Abstracts San Diego, CA. J Immunother 31: 951, 2008.
38. Karapanagiotou E, Pandha H, Hall G, Chester J, Melcher A, De Bono J, Gore M, Nutting C and Harrington K: Phase I trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients with advanced solid cancers. In: International Society for Biological Therapy of Cancer 23rd Annual Meeting Abstracts San Diego, CA. J Immunother 31: 952, 2008.